10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2018 | |||
Consolidated Statements of Operations | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 28, 2019) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Revenues: | |||
| Revenues | $ 193,919 | 184,765 | 177,526 |
| Net investment income | 660 | 21 | 20 |
| Total revenues | 194,579 | 184,786 | 177,546 |
| Operating costs: | |||
| Cost of products sold | 156,447 | 153,448 | 146,533 |
| Benefit costs | 6,594 | 2,810 | 2,179 |
| Goodwill impairments | 6,149 | 181 | 0 |
| Operating expenses | 21,368 | 18,809 | 18,448 |
| Total operating costs | 190,558 | 175,248 | 167,160 |
| Operating income | 4,021 | 9,538 | 10,386 |
| Interest expense | 2,619 | 1,062 | 1,078 |
| Loss on early extinguishment of debt | 0 | 0 | 643 |
| Other expense (income) | (4) | 208 | 28 |
| Income before income tax provision | 1,406 | 8,268 | 8,637 |
| Income tax provision | 2,002 | 1,637 | 3,317 |
| Income (loss) from continuing operations | (596) | 6,631 | 5,320 |
| Loss from discontinued operations, net of tax | 0 | (8) | (1) |
| Net income (loss) | (596) | 6,623 | 5,319 |
| Net (income) loss attributable to noncontrolling interests | 2 | (1) | (2) |
| Net income (loss) attributable to CVS Health | (594) | 6,622 | 5,317 |
| Basic earnings (loss) per share: | |||
| Income (loss) from continuing operations attributable to CVS Health (in dollars per share) | (0.57) | 6.48 | 4.93 |
| Loss from discontinued operations attributable to CVS Health (in dollars per share) | 0.00 | (0.01) | 0.00 |
| Net income (loss) attributable to CVS Health (in dollars per share) | (0.57) | 6.47 | 4.93 |
| Weighted average basic shares outstanding (in shares) | 1,044 | 1,020 | 1,073 |
| Diluted earnings (loss) per share: | |||
| Income (loss) from continuing operations attributable to CVS Health (in dollars per share) | (0.57) | 6.45 | 4.91 |
| Loss from discontinued operations attributable to CVS Health (in dollars per share) | 0.00 | (0.01) | 0.00 |
| Net income (loss) attributable to CVS Health (in dollars per share) | (0.57) | 6.44 | 4.90 |
| Weighted average diluted shares outstanding (in shares) | 1,044 | 1,024 | 1,079 |
| Dividends declared per share (in dollars per share) | 2.00 | 2.00 | 1.70 |
| Products and Services | |||
| Products | |||
| Revenues | 183,910 | 180,063 | 173,377 |
| Premiums | |||
| Revenues | 8,184 | 3,558 | 3,069 |
| Services | |||
| Revenues | 1,825 | 1,144 | 1,080 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2018 | |||
Consolidated Statements of Comprehensive Income | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 28, 2019) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Net income (loss) | $ (596) | 6,623 | 5,319 |
| Other comprehensive income (loss), net of tax: | |||
| Net unrealized investment gains | 97 | 0 | 0 |
| Foreign currency translation adjustments | (29) | (2) | 38 |
| Net cash flow hedges | 330 | (10) | 2 |
| Pension and other postretirement benefits | (124) | 152 | 13 |
| Other comprehensive income | 274 | 140 | 53 |
| Comprehensive income (loss) | (322) | 6,763 | 5,372 |
| Comprehensive (income) loss attributable to noncontrolling interests | 2 | (1) | (2) |
| Comprehensive income (loss) attributable to CVS Health | (320) | 6,762 | 5,370 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2018 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 28, 2019) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Cash flows from operating activities: | |||
| Cash receipts from customers | $ 186,519 | 176,594 | 172,310 |
| Cash paid for inventory and prescriptions dispensed by retail network pharmacies | (148,821) | (146,469) | (140,312) |
| Insurance benefits paid | (7,057) | (2,810) | (2,199) |
| Cash paid to other suppliers and employees | (17,234) | (15,348) | (15,478) |
| Interest and investment income received | 644 | 21 | 20 |
| Interest paid | (2,803) | (1,072) | (1,140) |
| Income taxes paid | (2,383) | (2,909) | (3,060) |
| Net cash provided by operating activities | 8,865 | 8,007 | 10,141 |
| Cash flows from investing activities: | |||
| Proceeds from sales and maturities of investments | 817 | 61 | 91 |
| Purchases of investments | (692) | (137) | (80) |
| Purchases of property and equipment | (2,037) | (1,918) | (2,224) |
| Proceeds from sale-leaseback transactions | 0 | 265 | 230 |
| Acquisitions (net of cash acquired) | (42,226) | (1,181) | (524) |
| Proceeds from sale of subsidiary and other assets | 832 | 0 | 0 |
| Other | 21 | 33 | 37 |
| Net cash used in investing activities | (43,285) | (2,877) | (2,470) |
| Cash flows from financing activities: | |||
| Net repayments of short-term debt | (556) | (598) | 1,874 |
| Proceeds from issuance of long-term debt | 44,343 | 0 | 3,455 |
| Repayments of long-term debt | (5,522) | 0 | (5,943) |
| Purchase of noncontrolling interest in subsidiary | 0 | 0 | (39) |
| Payment of contingent consideration | 0 | 0 | (26) |
| Derivative settlements | 446 | 0 | 0 |
| Repurchase of common stock | 0 | (4,361) | (4,461) |
| Dividends paid | (2,038) | (2,049) | (1,840) |
| Proceeds from exercise of stock options | 242 | 329 | 296 |
| Payments for taxes related to net share settlement of equity awards | (97) | (71) | (72) |
| Other | 1 | (1) | (5) |
| Net cash provided by (used in) financing activities | 36,819 | (6,751) | (6,761) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (4) | 1 | 2 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 2,395 | (1,620) | 912 |
| Cash, cash equivalents and restricted cash at the end of the period | 1,900 | 3,520 | |
| Cash, cash equivalents and restricted cash at the end of the period | 4,295 | 1,900 | 3,520 |
| Reconciliation of net income (loss) to net cash provided by operating activities: | |||
| Net income (loss) | (596) | 6,623 | 5,319 |
| Reconciliation of net loss to net cash provided by operating activities: | |||
| Depreciation and amortization | 2,718 | 2,479 | 2,475 |
| Goodwill impairments | 6,149 | 181 | 0 |
| Losses on settlements of defined benefit pension plans | 0 | 187 | 0 |
| Stock-based compensation | 280 | 234 | 222 |
| Loss on early extinguishment of debt | 0 | 0 | 643 |
| Deferred income taxes | 87 | (1,334) | 18 |
| Other noncash items | 339 | 53 | 135 |
| Change in operating assets and liabilities, net of effects from acquisitions: | |||
| Accounts receivable, net | (1,139) | (941) | (243) |
| Inventories | (1,153) | (514) | (742) |
| Other assets | (3) | (338) | (8) |
| Accounts payable and pharmacy claims and discounts payable | 2,489 | 1,710 | 2,189 |
| Health care costs payable and other insurance liabilities | (471) | 0 | (19) |
| Other liabilities | 165 | (333) | 152 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
CVS HEALTH CORP | ||
Ticker: CVS Fiscal Year: 2018 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2018 10-K (Filed: Feb 28, 2019) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2018 | Dec 31, 2017 | |
| Assets: | ||
| Cash and cash equivalents | $ 4,059 | 1,696 |
| Investments | 2,522 | 111 |
| Accounts receivable, net | 17,631 | 13,181 |
| Inventories | 16,450 | 15,296 |
| Other current assets | 4,581 | 945 |
| Total current assets | 45,243 | 31,229 |
| Long-term investments | 15,732 | 112 |
| Property and equipment, net | 11,349 | 10,292 |
| Goodwill | 78,678 | 38,451 |
| Intangible assets, net | 36,524 | 13,630 |
| Separate accounts assets | 3,884 | 0 |
| Other assets | 5,046 | 1,417 |
| Total assets | 196,456 | 95,131 |
| Liabilities: | ||
| Accounts payable | 8,925 | 8,863 |
| Pharmacy claims and discounts payable | 12,302 | 10,355 |
| Health care costs payable | 5,210 | 5 |
| Policyholders funds | 2,939 | 0 |
| Accrued expenses | 10,711 | 6,581 |
| Other insurance liabilities | 1,937 | 23 |
| Short-term debt | 720 | 1,276 |
| Current portion of long-term debt | 1,265 | 3,545 |
| Total current liabilities | 44,009 | 30,648 |
| Long-term debt | 71,444 | 22,181 |
| Deferred income taxes | 7,677 | 2,996 |
| Separate accounts liabilities | 3,884 | 0 |
| Other long-term insurance liabilities | 8,119 | 334 |
| Other long-term liabilities | 2,780 | 1,277 |
| Total liabilities | 137,913 | 57,436 |
| Commitments and contingencies (Note 16) | ||
| Shareholders equity: | ||
| CVS Health shareholders equity: | ||
| Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding | 0 | 0 |
| Common stock, par value $0.01: 3,200 shares authorized; 1,720 shares issued and 1,295 shares outstanding at December 31, 2018 and 1,712 shares issued and 1,014 shares outstanding at December 31, 2017 and capital surplus | 45,440 | 32,096 |
| Treasury stock, at cost: 425 shares at December 31, 2018 and 698 shares at December 31, 2017 | (28,228) | (37,796) |
| Retained earnings | 40,911 | 43,556 |
| Accumulated other comprehensive income (loss) | 102 | (165) |
| Total CVS Health shareholders equity | 58,225 | 37,691 |
| Noncontrolling interests | 318 | 4 |
| Total shareholders equity | 58,543 | 37,695 |
| Total liabilities and shareholders equity | 196,456 | 95,131 |
| External Links | |
| CVS HEALTH CORP (CVS) Fiscal Year 2018 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |